ABSTRACT SUBMISSION


Deadline for abstract submission is
September 11, 2020

SUBMIT NOW YOUR ABSTRACT

INSTRUCTIONS FOR ABSTRACT SUBMISSION

Before preparing and typing your abstract for the ABSTRACT SUBMISSION, please read carefully the following instructions:

  • Abstracts can be submitted via the online Abstract Submission Service only. Abstracts sent in any other way will not be accepted.
  • Abstract must be submitted and presented in English.
  • The complete abstract must not exceed 170 characters for the TITLE and 250 words / 2000 characters for the BODY.
  • TITLE: capitalize the entire title. Spell out words. Do not use abbreviations and check that your title is complete in case you copy and paste it into the field.
  • AUTHORS/AFFILIATIONS: you may enter up to 20 authors in the authors list and 10 affiliations. The presenting must be part of the authors list included in the submitted abstract. The names of authors will be published as listed on the submission form. Please make sure you have entered the full list of authors. The authors’ order and details (names, cities, country) will be published as entered in the form.
  • TEXT: begin the text on a new line.
  • Do not include authors, institutions, city and abbreviations in the title or in the text.
  • Do not include grant acknowledgements in the abstract content. Do not cite keywords or references in the abstract, as they are not allowed and will be deleted.
  • Abstract will be accepted according to scientific merit.
  • Notification about the acceptance/rejection of the abstract will be sent to the corresponding author by e-mail after the relevant evaluations.

NOTERegistration is compulsory in order to present an abstract during the Meeting. 

For any information: progress2020.abs@aimgroup.eu

INSTRUCTIONS FOR ABSTRACT SUBMISSION

Before preparing and typing your abstract for the ABSTRACT SUBMISSION, please read carefully the following instructions:

  • Abstracts can be submitted via the online Abstract Submission Service only. Abstracts sent in any other way will not be accepted.
  • Abstract must be submitted and presented in English.
  • The complete abstract must not exceed 170 characters for the TITLE and 250 words / 2000 characters for the BODY.
  • TITLE: capitalize the entire title. Spell out words. Do not use abbreviations and check that your title is complete in case you copy and paste it into the field.
  • AUTHORS/AFFILIATIONS: you may enter up to 20 authors in the authors list and 10 affiliations. The presenting must be part of the authors list included in the submitted abstract. The names of authors will be published as listed on the submission form. Please make sure you have entered the full list of authors. The authors’ order and details (names, cities, country) will be published as entered in the form.
  • TEXT: begin the text on a new line.
  • Do not include authors, institutions, city and abbreviations in the title or in the text.
  • Do not include grant acknowledgements in the abstract content. Do not cite keywords or references in the abstract, as they are not allowed and will be deleted.
  • Abstract will be accepted according to scientific merit.
  • Notification about the acceptance/rejection of the abstract will be sent to the corresponding author by e-mail after the relevant evaluations.

NOTERegistration is compulsory in order to present an abstract during the Meeting. 

For any information: progress2020.abs@aimgroup.eu


TOPICS FOR ABSTRACT SUBMISSION

  • BASIC ELECTROPHYSIOLOGY
  • GENETIC IN ARRHYTHMIAS
  • CELL AND GENE THERAPIES
  • SICK SINUS SYNDROME
  • ATRIAL FIBRILLATION: DIAGNOSIS, PHARMACOLOGICAL TREATMENT
  • AV AND INTRAVENTRICULAR CONDUCTION DISTURBANCES
  • SUDDEN DEATH
  • NON INVASIVE SUDDEN DEATH RISK STRATIFICATION
  • HEART FAILURE
  • GENETIC ARRHYTHMIAS
  • HYPERTROPHIC CARDIOMIOPATHY
  • PEDIATRIC ARRHYTHMIAS MANAGEMENT
  • SLEEP APNEA
  • SYNCOPE
  • ECHOCARDIOGRAPHY IN ARRHYTHMOLOGY
  • SPORT AND ARRHYTHMIAS
  • IDIOPATHIC VENTRICULAR FIBRILLATION
  • BRUGADA SYNDROME
  • INHERITED ARRHYTHMIAS
  • AUTONOMIC NERVOUS SYSTEM AND CARDIAC ARRHYTHMIAS
  • NEW ORAL ANTICOAGULANTS (DOACs)
  • ELECTRICAL STORM
  • WEARABLE CARDIOVERTER DEFRIBILLATOR
  • CRYPTOGENETIC STROKE AND ATRIAL FIBRILLATION
  • CHANNELOPATHIES
  • CATHETER ABLATION: DIFFERENT TECHNIQUES AND MAPPING SYSTEMS
  • CATHETER ABLATION OF ATRIAL FIBRILLATION
  • CATHETER ABLATION OF ATRIAL FLUTTER
  • CATHETER ABLATION OF ATRIAL TACHYCARDIA
  • CATHETER ABLATION OF AV NODAL TACHYCARDIA
  • CATHETER ABLATION OF ANOMALOUS PATHWAYS
  • CATHETER ABLATION OF VENTRICULAR TACHYCARDIA
  • CATHETER ABLATION OF VENTRICULAR FIBRILLATION
  • SURGICAL ABLATION
  • IMPLANTABLE PACING DEVICES AND LEADS
  • NEW AUTOMATIC ALGORITMS FOR DETECTION AND PACING OPTIMIZATION
  • CARDIAC RESYNCHRONIZATION THERAPY, MULTIPOLAR LEADS, AND MULTISITE PACING
  • IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS
  • LEADLESS PACEMAKERS
  • SUBCUTANEOUS DEFIBRILLATORS
  • INJECTABLE LOOP-RECORDERS
  • BAROREFLEX ACTIVATION THERAPY
  • CIEDs REMOTE MONITORING
  • LEADS EXTRACTION
  • CIEDs INFECTIONS: PREVENTION AND MANAGEMENT
  • HIS BUNDLE PACING
  • NO X-RAY INVASIVE PROCEDURES
  • LAAC: INDICATIONS, DEVICES, AND TECHNIQUES

  • BASIC ELECTROPHYSIOLOGY
  • GENETIC IN ARRHYTHMIAS
  • CELL AND GENE THERAPIES
  • SICK SINUS SYNDROME
  • ATRIAL FIBRILLATION: DIAGNOSIS, PHARMACOLOGICAL TREATMENT
  • AV AND INTRAVENTRICULAR CONDUCTION DISTURBANCES
  • SUDDEN DEATH
  • NON INVASIVE SUDDEN DEATH RISK STRATIFICATION
  • HEART FAILURE
  • GENETIC ARRHYTHMIAS
  • HYPERTROPHIC CARDIOMIOPATHY
  • PEDIATRIC ARRHYTHMIAS MANAGEMENT
  • SLEEP APNEA
  • SYNCOPE
  • ECHOCARDIOGRAPHY IN ARRHYTHMOLOGY
  • SPORT AND ARRHYTHMIAS
  • IDIOPATHIC VENTRICULAR FIBRILLATION
  • BRUGADA SYNDROME
  • INHERITED ARRHYTHMIAS
  • AUTONOMIC NERVOUS SYSTEM AND CARDIAC ARRHYTHMIAS
  • NEW ORAL ANTICOAGULANTS (DOACs)
  • ELECTRICAL STORM
  • WEARABLE CARDIOVERTER DEFRIBILLATOR
  • CRYPTOGENETIC STROKE AND ATRIAL FIBRILLATION
  • CHANNELOPATHIES
  • CATHETER ABLATION: DIFFERENT TECHNIQUES AND MAPPING SYSTEMS
  • CATHETER ABLATION OF ATRIAL FIBRILLATION
  • CATHETER ABLATION OF ATRIAL FLUTTER
  • CATHETER ABLATION OF ATRIAL TACHYCARDIA
  • CATHETER ABLATION OF AV NODAL TACHYCARDIA
  • CATHETER ABLATION OF ANOMALOUS PATHWAYS
  • CATHETER ABLATION OF VENTRICULAR TACHYCARDIA
  • CATHETER ABLATION OF VENTRICULAR FIBRILLATION
  • SURGICAL ABLATION
  • IMPLANTABLE PACING DEVICES AND LEADS
  • NEW AUTOMATIC ALGORITMS FOR DETECTION AND PACING OPTIMIZATION
  • CARDIAC RESYNCHRONIZATION THERAPY, MULTIPOLAR LEADS, AND MULTISITE PACING
  • IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS
  • LEADLESS PACEMAKERS
  • SUBCUTANEOUS DEFIBRILLATORS
  • INJECTABLE LOOP-RECORDERS
  • BAROREFLEX ACTIVATION THERAPY
  • CIEDs REMOTE MONITORING
  • LEADS EXTRACTION
  • CIEDs INFECTIONS: PREVENTION AND MANAGEMENT
  • HIS BUNDLE PACING
  • NO X-RAY INVASIVE PROCEDURES
  • LAAC: INDICATIONS, DEVICES, AND TECHNIQUES